95 related articles for article (PubMed ID: 11064911)
21. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
22. [Model of screening for prostatic cancer among patients with prostate specific antigen concentration of 4-10 ng/ml in blood].
Karazanashvili GG; Managadze LG
Urologiia; 2000; (6):37-41. PubMed ID: 11186321
[TBL] [Abstract][Full Text] [Related]
23. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
24. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
Pelzer AE; Tewari A; Bektic J; Berger AP; Frauscher F; Bartsch G; Horninger W
Urology; 2005 Nov; 66(5):1029-33. PubMed ID: 16286118
[TBL] [Abstract][Full Text] [Related]
25. [Diagnosis of cancer of the prostate (I): Advancements in knowledge and practice since the consensus conference of 1989. The "Cancer of the Prostate" subcommittee of the Committee of Oncology of the French Association of Urology].
Villers A; Grosclaude P; Haillot O; Abbou CC; Richard F; Boccon-Gibod L
Prog Urol; 1997 Jun; 7(3):508-15. PubMed ID: 9273082
[TBL] [Abstract][Full Text] [Related]
26. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
Sözen S; Eskicorapci S; Küpeli B; Irkilata L; Altinel M; Ozer G; Uygur C; Alkibay T; Ozen H
Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190
[TBL] [Abstract][Full Text] [Related]
27. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
[TBL] [Abstract][Full Text] [Related]
28. Age-related reference intervals for free and total prostate-specific antigen in a Singaporean population.
Saw S; Aw TC
Pathology; 2000 Nov; 32(4):245-9. PubMed ID: 11186419
[TBL] [Abstract][Full Text] [Related]
29. The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels.
Pelzer AE; Volgger H; Bektic J; Berger AP; Rehder P; Bartsch G; Horninger W
BJU Int; 2005 Nov; 96(7):995-8. PubMed ID: 16225515
[TBL] [Abstract][Full Text] [Related]
30. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
Bourel M; Ardaillou R;
Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
[TBL] [Abstract][Full Text] [Related]
32. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.
Chun FK; Hutterer GC; Perrotte P; Gallina A; Valiquette L; Benard F; McCormack M; Briganti A; Ionescu C; Jeldres C; Guay JP; Saad F; Karakiewicz PI
BJU Int; 2007 Jul; 100(1):37-41. PubMed ID: 17488305
[TBL] [Abstract][Full Text] [Related]
33. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
[TBL] [Abstract][Full Text] [Related]
34. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
[TBL] [Abstract][Full Text] [Related]
35. An evaluation of prostate-specific antigen as a screening test for prostate cancer.
Dorr VJ; Williamson SK; Stephens RL
Arch Intern Med; 1993 Nov; 153(22):2529-37. PubMed ID: 7694555
[TBL] [Abstract][Full Text] [Related]
36. [Multiparametric MRI for prostate cancer screening].
Hoeks CM; Fütterer JJ; Somford DM; van Oort IM; Huisman H; Barentsz JO
Ned Tijdschr Geneeskd; 2009; 153():B487. PubMed ID: 20003566
[TBL] [Abstract][Full Text] [Related]
37. Development of the Abbott AxSYM Free PSA assay: performance characteristics and preliminary clinical evaluation.
Dowell B; Jacobson L; Friese J; Rapp J; Miceli C; Loewen N; Lauren L; Salle J; Slota J; Seguado O; Weigand R
Anticancer Res; 1997; 17(4B):3037-8. PubMed ID: 9329595
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer screening.
Sikaris K
Pathology; 2012 Feb; 44(2):99-109. PubMed ID: 22198258
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen testing across the spectrum of prostate cancer.
Haythorn MR; Ablin RJ
Biomark Med; 2011 Aug; 5(4):515-26. PubMed ID: 21861672
[TBL] [Abstract][Full Text] [Related]
40. The effect of lowering the prostate-specific antigen normal cutoff on referral rates to urology.
Shenker BS; Stern J
J Am Board Fam Med; 2012; 25(6):927-9. PubMed ID: 23136335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]